Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 4.4% – Should You Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded down 4.4% during trading on Friday . The stock traded as low as $3.49 and last traded at $3.51. 140,111 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 2,867,328 shares. The stock had previously closed at $3.67.

Wall Street Analyst Weigh In

IRWD has been the subject of several analyst reports. Leerink Partners initiated coverage on Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Wells Fargo & Company lowered their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, August 9th. Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $12.00 to $4.00 in a research report on Thursday, August 8th. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Finally, Craig Hallum decreased their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.40.

Ironwood Pharmaceuticals Stock Performance

The company has a 50-day simple moving average of $4.13 and a two-hundred day simple moving average of $5.22.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The business had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm’s revenue was down 19.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.12 earnings per share. Sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares in the company, valued at $1,263,053.76. The trade was a 3.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 12.90% of the stock is owned by insiders.

Institutional Trading of Ironwood Pharmaceuticals

A number of institutional investors have recently modified their holdings of IRWD. CWM LLC lifted its position in shares of Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after buying an additional 2,345 shares during the last quarter. KBC Group NV increased its holdings in Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,198 shares in the last quarter. GAMMA Investing LLC increased its holdings in Ironwood Pharmaceuticals by 344.1% in the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 8,156 shares in the last quarter. First Dallas Securities Inc. acquired a new position in Ironwood Pharmaceuticals in the 2nd quarter worth about $73,000. Finally, Diversified Trust Co acquired a new position in Ironwood Pharmaceuticals in the 3rd quarter worth about $52,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.